# A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Oral Doses of HRS-7085 Tablets in Healthy Subjects, With Assessment of Food Effects

> **NCT06175949** · PHASE1 · UNKNOWN · sponsor: **Shandong Suncadia Medicine Co., Ltd.** · enrollment: 70 (estimated)

## Conditions studied

- Inflammatory Bowel Disease

## Interventions

- **DRUG:** HRS-7085 Tablets
- **DRUG:** HRS-7085 simulant

## Key facts

- **NCT ID:** NCT06175949
- **Lead sponsor:** Shandong Suncadia Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12
- **Primary completion:** 2024-06
- **Final completion:** 2024-07
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2023-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06175949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06175949, "A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Oral Doses of HRS-7085 Tablets in Healthy Subjects, With Assessment of Food Effects". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06175949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*